Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures - A single-center study
Autore:
Jelic, S; Babovic, N; Stamatovic, L; Kreacic, M; Matkovic, S; Popov, I;
Indirizzi:
Inst Oncol & Radiol Serbia, Dept Med Oncol, YU-11000 Belgrade, Yugoslavia Inst Oncol & Radiol Serbia Belgrade Yugoslavia YU-11000 rade, Yugoslavia
Titolo Testata:
MEDICAL ONCOLOGY
fascicolo: 3, volume: 18, anno: 2001,
pagine: 189 - 195
SICI:
1357-0560(2001)18:3<189:VFMCMA>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
ADVANCED MALIGNANT-MELANOMA; PHASE-II TRIAL; CYTOSINE-ARABINOSIDE; DARTMOUTH REGIMEN; RANDOMIZED TRIAL; INTERFERON-ALPHA; ONCOLOGY GROUP; CISPLATIN; TAMOXIFEN; INTERLEUKIN-2;
Keywords:
melanoma; metastatic; primary chemotherapy; salvage chemotherapy; vinblastine; carboplatin;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
24
Recensione:
Indirizzi per estratti:
Indirizzo: Jelic, S Inst Oncol & Radiol Serbia, Dept Med Oncol, Pasterova 14, YU-11000 Belgrade, Yugoslavia Inst Oncol & Radiol Serbia Pasterova 14 Belgrade Yugoslavia YU-11000
Citazione:
S. Jelic et al., "Vinblastin-carboplatin for metastatic cutaneous melanoma as first-line chemotherapy and in dacarbazine failures - A single-center study", MED ONCOL, 18(3), 2001, pp. 189-195

Abstract

First-line treatments of metastatic melanoma are usually decarbazine (DTIC) and/or alpha -interferon based, with response rates in the range of at most 20-30%. In this study, initiated, in fact, by a temporary DTIC shortage in the country, we have assessed the efficacy and toxicity of a vinblastine- carboplatin regimen for metastatic melanoma. The regimen was subsequently applied in two cohorts of patients: a chemotherapy-naive one and in DTIC failures (because the regimen was claimed non-cross-resistant). The regimencontained 6 mg/m(2) vinblastine on d 1 and 450 mg/m(2) carboplatin on d 1 for 3 wk. In the chemotherapy-naive cohort, 50 patients were included, 29 males and 21 females, median age 54 yr (range: 33-68), performance status 0+1 for 26 patients and 2+3 for 24 patients. Forty-eight patients were evaluable for activity. The response was the following: complete response (CR), 1/48 (2%); partial response (PR), 13/48 (27%); stable disease (SD), 20/48 (42%); progressive disease (PD), 14/48 (29%). The overall response rate was 14/48 (29%). The median response duration was 7 mo (range: 3-14); the mediantime to progression was 4 mo (range: 2-14). Toxicity included granulocytopenia and thrombocytopenia grade IV in 3/50 patients and nausea grade II in 8/50 patients. In the DTIC-failures cohort, 58 patients were included, 38 males and 20 females, median age 51 yr (range: 20-65), performance status 0+1 for 25 patients and 2+3 for 33 patients. All 58 patients were evaluable for activity. The response was the following: CR 3/58 (5%), PR 4/58 (7%), SD10/58 (17%), PD 41/58 (71%). The overall response rate was 7/58 (12%). Themedian response duration was 11 mo (range: 3-24); the median time to progression was 4 mo (range: 2-24). Toxicities included granulocytopenia grade IV in 4/58 patients and nausea grade II in 4/58 patients. Thus, despite the fact that the regimen achieved a response rate comparable to DTIC in a first-line setting, the lack of cross-resistance did not prevent it from being of limited activity in DTIC failures, although, even in this group, severallong-lasting responses and stabilizations were noted.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/07/20 alle ore 02:26:51